Forbes High Rank of Personal Cell Sciences Highlights Value in American CryoStem

American CryoStem (CRYO)

In the 2012 edition of its Top 10 Fashion and Beauty Startups, ranked only one company, online retailer Mode-sty, above Personal Cell Sciences.  Personal Cell Sciences, a privately-held corporation, has brought to market “U Autologous,” a cutting-edge anti-aging skincare whose ingredients include a user’s own stem cells.  The crux of the recipe is pretty simple to grasp and easily understandable as to why it’s effective.  Adipose, or fat, stem cells are removed from a customer through liposuction, sent off for processing and transformed into a skin product containing the youthful cells to keep skin supple and wrinkle-free.  The remaining cells are stored for subsequent orders or for other additional future uses, which given new innovations in stem cell therapies, could ultimately be a wide array of applications.

But the company is private, you may say.  That is indeed true, but Personal Cell Sciences is owned by John Arnone, the Chief Executive Officer at American CryoStem Corp. (OTCQB: CRYO), a fact that ties these two companies together in more ways than just the having the same top exec.

Eatontown, New Jersey-based American CryoStem is an upstart biotech company focused on marketing its clinical processing services and patented products for adipose tissue and Adipose Derived Adult Stem Cells (ADSCs).  The company is the contract manufactures for U Autologous as well as the storage facility for the stem cells.  American CryoStem utilizes its patented animal-free media to culture an individual’s stem cells to create the key ingredient in U Autologous, Autokine-CMTM, which contains the individual’s proteins, growth factors and cytokines collected from their ADSCs.  Located near New York City, the fashion and money hub of the world with a lengthy list of plastic surgeons selling the product to patients, the new clinically-proven product is quickly emerging as a blockbuster.  While the skin product got the immediate notoriety, the stem cells can also be used for augmentations – such as breast or buttock – and carries the possibility to replace riskier materials that are used every day in those procedures.

While these products drive revenue for American CryoStem already, the patented media should also be a focus of investors for what it could bring to the company and its stakeholders.  Cultures are used in virtually every aspect of medicine from early development of compounds and regenerative medicines to tests in medical clinics.  The most-commonly used medium, or albumin, today for storing cell cultures or for in vitro diagnostics is fetal bovine serum.  Yes, it comes from cows (fetuses, actually, as the name implies).  American CryoStem’s product is human-derived (eliminating ethical and biological arguments out there today about the use of bovine-derived material) and could prove a superior product in general.

The company has been issued one patent, with four more pending, covering a broad base of 12 different types of mediums to protect its intellectual property and establish it as the clear leader in the space.

Approximately three-quarters of a million liters of fetal bovine serum are sold each year, making it a better than $500 million industry.  European regulators are starting to make the transition to albumins that cannot have touched an animal in the manufacturing chain.  American CryoStem’s issued patent for human albumin covers the European Union.  To that end, it is discernible that other countries will soon follow, positioning American CryoStem as the potential industry stalwart and in a unique spot for serious growth in the sector.  That is in addition to its cryopreservation services, U Autologous revenue stream, wound care product and various other potential applications related to regenerative medicines.  Proper due diligence of this up-and-comer is, as always, encouraged.

American CryoStem (CRYO) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix

Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)

Ecosphere Technologies, Inc. (OTCBB: ESPH) said Monday that it delivered two more Ozonix EF80 units to Hydrozonix LLC as part of a long-term contract with water treatment solutions company. Hydrozonix is a strategic alliance of a consortium of the principals at Phillips and Jordan, Inc., the Siboney Group and PBA Holdings that provides mobile, eco-friendly

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0)

By Rex Graham A Glaxo Smith Kline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vical, Inc. (VICL), and Sanofi Pasteur (SNY) offer new hope for an effective vaccine treatment. A Yale University study published in the Nov. 15, 2012,

Senate Approves Tax Hikes and Delay in Spending Cuts

Senate Approves Tax Hikes and Delay in Spending Cuts(0)

Technically, the United States has gone over the fiscal cliff with January 1 arriving before a new budget was passed to avert a series of automatic tax increases and deep spending cuts. But, the Senate said Tuesday morning that the White House and Senate Republicans have come to terms to raise taxes on households bringing-in

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)

Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013.  Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement. Previously, Smith spent ten

Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump

Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)

Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announced that it has entered into a common stock purchase agreement

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.